{
    "clinical_study": {
        "@rank": "168347", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the effectiveness of BRAF inhibitors and current\n      therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600\n      mutation. Patients will be treated per the locally approved therapeutic options in clinical\n      practice. The observation period for each patient will be up to 24 months."
        }, 
        "brief_title": "An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age at diagnosis\n\n          -  Histologically confirmed new diagnosis of unresectable or metastatic melanoma\n\n          -  Patients with tumor samples available for assessment of BRAF V600 mutation\n\n        Exclusion Criteria:\n\n          -  Prior systemic therapy for metastatic disease\n\n          -  Participation in interventional clinical trials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with newly diagnosed unresectable or metastatic melanoma"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143999", 
            "org_study_id": "ML29031"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Genova", 
                    "country": "Italy", 
                    "state": "Liguria", 
                    "zip": "16132"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: L&apos;Agenzia Italiana del Farmaco (AIFA)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Best Overall Response Rate (BORR)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "ECOG performance status", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}